150 related articles for article (PubMed ID: 29242403)
1. Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?
Enilorac B; Lasnon C; Nganoa C; Fruchart C; Gac AC; Damaj G; Aide N
J Nucl Med; 2018 Jul; 59(7):1049-1055. PubMed ID: 29242403
[TBL] [Abstract][Full Text] [Related]
2. The use of a proposed updated EARL harmonization of
Ly J; Minarik D; Edenbrandt L; Wollmer P; Trägårdh E
EJNMMI Res; 2019 Jul; 9(1):65. PubMed ID: 31346805
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
[TBL] [Abstract][Full Text] [Related]
4. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
Houdu B; Lasnon C; Licaj I; Thomas G; Do P; Guizard AV; Desmonts C; Aide N
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):421-428. PubMed ID: 30218317
[TBL] [Abstract][Full Text] [Related]
5. Assessment of alteration in liver
Salomon T; Nganoa C; Gac AC; Fruchart C; Damaj G; Aide N; Lasnon C
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):941-950. PubMed ID: 29279943
[TBL] [Abstract][Full Text] [Related]
6. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.
Quak E; Le Roux PY; Hofman MS; Robin P; Bourhis D; Callahan J; Binns D; Desmonts C; Salaun PY; Hicks RJ; Aide N
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2072-82. PubMed ID: 26219870
[TBL] [Abstract][Full Text] [Related]
7.
Lasnon C; Majdoub M; Lavigne B; Do P; Madelaine J; Visvikis D; Hatt M; Aide N
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2324-2335. PubMed ID: 27325312
[TBL] [Abstract][Full Text] [Related]
8. Interobserver Agreement of Interim and End-of-Treatment
Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
[TBL] [Abstract][Full Text] [Related]
9. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.
Lasnon C; Salomon T; Desmonts C; Dô P; Oulkhouir Y; Madelaine J; Aide N
Ann Nucl Med; 2017 Feb; 31(2):125-134. PubMed ID: 27812791
[TBL] [Abstract][Full Text] [Related]
10. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
Toledano MN; Vera P; Tilly H; Jardin F; Becker S
PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
[TBL] [Abstract][Full Text] [Related]
11. Does PET SUV Harmonization Affect PERCIST Response Classification?
Quak E; Le Roux PY; Lasnon C; Robin P; Hofman MS; Bourhis D; Callahan J; Binns DS; Desmonts C; Salaun PY; Hicks RJ; Aide N
J Nucl Med; 2016 Nov; 57(11):1699-1706. PubMed ID: 27283930
[TBL] [Abstract][Full Text] [Related]
12. A retrospective head-to-head comparison of the Lugano classification and PERCIST for FDG-PET/CT response assessment in diffuse large B-cell lymphoma.
Nielsen NB; Gerke O; Nielsen AL; Juul-Jensen K; Larsen TS; Møller MB; Hildebrandt MG
Clin Physiol Funct Imaging; 2024 Jan; 44(1):70-78. PubMed ID: 37501554
[TBL] [Abstract][Full Text] [Related]
13. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.
Lasnon C; Desmonts C; Quak E; Gervais R; Do P; Dubos-Arvis C; Aide N
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):985-96. PubMed ID: 23564036
[TBL] [Abstract][Full Text] [Related]
14. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
Kim J; Song YS; Lee JS; Lee WW; Kim SE
Leuk Lymphoma; 2018 Feb; 59(2):340-347. PubMed ID: 28629257
[TBL] [Abstract][Full Text] [Related]
16. Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the ΔSUVmax method.
Ng DZ; Lee CY; Lam WW; Tong AK; Tan SH; Khoo LP; Tan YH; Chiang J; Chang EW; Chan JY; Poon EY; Somasundaram N; Farid H Rashid M; Tao M; Lim ST; Yang VS
Leuk Lymphoma; 2022 Jan; 63(1):256-259. PubMed ID: 34665693
[TBL] [Abstract][Full Text] [Related]
17. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
18. End-of-treatment
Allioux F; Gandhi D; Vilque JP; Nganoa C; Gac AC; Aide N; Lasnon C
Leuk Lymphoma; 2021 Dec; 62(12):2890-2898. PubMed ID: 34219589
[TBL] [Abstract][Full Text] [Related]
19. The variation of quantitative parameters and Deauville scores with different reconstruction algorithms in FDG PET/CT imaging of lymphoma patients.
Genc M; Yildirim N; Coskun N; Ozdemir E; Turkolmez S
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(6):388-392. PubMed ID: 37524200
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.
Itti E; Lin C; Dupuis J; Paone G; Capacchione D; Rahmouni A; Haioun C; Meignan M
J Nucl Med; 2009 Apr; 50(4):527-33. PubMed ID: 19289424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
